

Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GANLEX

Tocilizumab

A. Active patents

S.No.	Title	Assignee	Patent Details	Type Of Patent	Remarks
1.	An Antibody-Containing Solution Formulation	Chugai Seiyaku Kabushiki Kaisha	App No/Grant No: IN229692 (1778/CHENP/2004): Filing Date: 09/08/2004 Grant Date: 19/02/2009 Expected Expiry Date: 14/02/2023 Form 27: Filed Worked In India	Injectable Formulation Tocilizumab	Patent Barrier. However, formulation can be worked around.
2.	Improved Antibody Molecules	Chugai Seiyaku Kabushiki Kaisha	App No/Grant No: IN278603 (2063/DELNP/2010) Filing Date: 23/03/2010 Grant Date: 27/12/2016 Expected Expiry Date: 25/09/2029 Form 27: Not Yet Worked In India	Pharmaceutical Composition Of Derivatives Form Of Tocilizumab Patent	Patent Barrier However, can be worked around.

B. Pending applications

S.no.	Title	Assignee	Application details	Type of patent	Remarks
1.	Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same	1. Sanofi Biotechnology 2. Regeneron Pharmaceuticals, Inc.	App no: IN201717018071 Filing Date: 31/05/2018 Published Date: 05/10/2018 Status: Est. Patent Expiry: 03/11/2036, if granted	Compositions and methods of treating	Currently, no patent barrier. Patent Watch recommended
2.	Stable pharmaceutical composition	Dr. Reddy's Laboratories Limited	App no: IN 201641001111 Filing Date: 12/01/2016 Published Date: 17/11/2017 Status: Est. Patent Expiry: 11/01/2037, if granted	Pharmaceutical formulation of tocilizumab	Currently, no patent barrier. Can be work around.
3.	Stable liquid pharmaceutical composition	Dr. Reddy's Laboratories Limited	App no: IN 201741013746 Filing Date: 18/04/2017 Published Date: 26/10/2018 Status: Published	stable liquid antibody formulation of tocilizumab	Currently, no patent barrier. Can be work around.

Commissioned by



Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

C. Expired/Lapsed applications

S.no.	Title	Assignee	Patent/Application details	Type of patent	Remarks
1.	Antibody-containing solution formulations	Chugai Seiyaku Kabushiki Kaisha	App no: 3898/CHENP/2008 (Divisional National Phase Application to IN229692) Priority date: 14/02/2002 Status: Withdrawn	Tocilizumab Formulation	No patent barrier
2.	Anti-il-6 receptor antibody	Chugai Seiyaku Kabushiki Kaisha	App no/Grant no: IN286348 (2097/DELNP/2010) Filing date: 25/03/2010 Grant date: 14/08/2017 Status: Ceased	Pharmaceutical composition and method for producing Tocilizumab	No patent barrier
3.	Improved antibody molecules	Chugai Seiyaku Kabushiki Kaisha	App No: 6429/DELNP/2015 (Divisional National Phase Application to IN278603) Filing Date: 21/07/2015 Status: Abandoned	Pharmaceutical composition of derivatives form of Tocilizumab	No patent barrier

Disclaimer:

Search results are up to 11th April 2020

GNANLex's Opinion / Report as hereinabove is to the best of our knowledge, true and accurate as of the date compiled based on available information. However, no guarantee is made as to its accuracy, reliability or completeness. The final user is expected to assume sole liability for any patent infringement that occurs by following our recommendations or using the information given. Before using, user should determine the suitability of the information for his intended use. The risk and liability, if any, in connection therewith, is solely that of the user.

Commissioned by

